BRD2 and neoplasm: TCR repertoire analysis revealed that multiple expanded TRB-CDR3 clonotypes observed in tumor, NAT, and PBMC at frequencies up to 3% at the time of surgery were maintained in peripheral blood at high frequency (up to 3.8%) one year later (Supplementary Figure 2B).